Is immunotherapy indicated for a patient with a completely resected ciliary body melanoma who now has a locally recurrent tumor with clear surgical margins?

Adjuvant Immunotherapy for Resected Ciliary Body Melanoma with Local Recurrence

Adjuvant immunotherapy should be considered for your patient with completely resected locally recurrent ciliary body melanoma, as this represents high-risk locoregional disease analogous to resected in-transit or microsatellite melanoma, for which adjuvant therapy is recommended despite limited prospective data.

Clinical Reasoning and Evidence Base

Classification of Local Recurrence as High-Risk Disease

Your patient's locally recurrent ciliary body melanoma with clear margins after re-resection represents a clinical scenario analogous to completely resected in-transit melanoma. The 2020 ESMO guidelines explicitly state that adjuvant therapy may be considered for patients with completely resected in-transit melanoma or microsatellites, including patients without evidence of nodal metastasis 1. The biological rationale is compelling: patients with resected locoregional recurrence face high risk of further relapse and death similar to other stage III melanoma categories where adjuvant therapy is indicated.

Key Considerations for Treatment Decision

The ESMO consensus acknowledges that resuming or initiating adjuvant therapy for completely resected locoregional recurrent melanoma remains controversial in the absence of prospective clinical data 1. However, several factors support treatment in your case:

• Treatment-naive status: If your patient was NOT receiving adjuvant therapy when the recurrence developed, this is a different scenario than progression on therapy. The guidelines note that patients relapsing despite adjuvant therapy might be considered resistant to that strategy 1.

• Complete resection with clear margins: This is the critical prerequisite. Your patient meets this criterion, placing them in the optimal category for adjuvant consideration.

• High recurrence risk: Local recurrence after initial complete resection signals aggressive tumor biology and substantially elevated risk of subsequent metastatic disease.

Specific Treatment Recommendations

For treatment-naive patients (no prior adjuvant therapy):

• Initiate adjuvant immunotherapy with anti-PD-1 monotherapy (pembrolizumab or nivolumab) as first-line option
• Alternative: Combination ipilimumab/nivolumab if higher-risk features present, though toxicity is substantially greater
• If BRAF V600 mutation positive: Consider dabrafenib/trametinib, particularly if immunotherapy contraindicated 1

For patients who recurred while on adjuvant therapy: The decision becomes more nuanced. The guidelines suggest these patients may be resistant to the initial strategy 1. However, "mixed responses" can occur, and oligoprogression doesn't always indicate futility. Consider:

• Switching therapy class (e.g., from targeted therapy to immunotherapy or vice versa)
• Continuing same therapy only if: excellent tolerance, long interval since treatment start, isolated recurrence suggesting oligoprogression
• Stopping therapy if: rapid recurrence, multiple sites, poor tolerance

Important Caveats and Pitfalls

Ciliary body melanoma specificity: While the provided evidence focuses on cutaneous melanoma, the biological principles apply. Recent case reports demonstrate that combination immunotherapy (nivolumab/ipilimumab) can achieve complete regression of metastatic cutaneous melanoma to ciliary body/choroid 2, supporting immunotherapy efficacy in this anatomic location.

Lack of direct evidence: No randomized trials specifically address your exact scenario. The recommendations extrapolate from:

• Adjuvant trials in stage III cutaneous melanoma
• Biological similarity between in-transit disease and local recurrence
• Emerging neoadjuvant data showing immunotherapy efficacy in high-risk resectable disease 3, 4

Monitoring considerations: Given the ocular location, coordinate closely with ophthalmology for surveillance. The recent literature suggests ctDNA monitoring may help predict recurrence and guide adjuvant therapy duration 4, though this remains investigational.

Practical Algorithm

1. Confirm complete resection with negative margins (already achieved in your case)
2. Determine BRAF mutation status if not already known
3. Assess prior treatment exposure:
   • If treatment-naive → Proceed with anti-PD-1 monotherapy
   • If prior adjuvant therapy → Consider switching therapy class
4. Evaluate contraindications to immunotherapy (active autoimmune disease, organ transplant)
5. Discuss toxicity profile and patient preferences
6. Initiate treatment within 12 weeks of surgery (standard adjuvant timing)

Strength of Recommendation

The evidence supporting this recommendation is Level V with Strength C 1, reflecting expert consensus rather than randomized trial data. However, the 100% consensus among ESMO panelists for adjuvant therapy in resected in-transit disease 1 provides strong professional agreement supporting this approach. The alternative—observation alone—leaves your patient at very high risk of metastatic progression without intervention.

The balance clearly favors treatment: the potential mortality benefit from preventing distant metastases outweighs the manageable toxicity risks of modern immunotherapy in this high-risk, completely resected scenario.